Disclosed herein are methods and compounds for treating an individual diagnosed with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML) by administering to the individual a combination comprising ibrutinib and Abexinostat. Also provided are methods for treating an ibrutinib-resistant CLL or an ibrutinib-resistant AML by administering to the individual a combination comprising ibrutinib and Abexinostat. Further provided are methods of reducing the development of ibrutinib resistance in an individual having either CLL or AML or preventing the development of ibrutinib resistance in an individual having CLL or AML by administering to the individual a combination comprising ibrutinib and Abexinostat.本文揭示治療被診斷患有慢性淋巴球性白血病(CLL)或急性骨髓性白血病(AML)的個體之方法與化合物,其係將包含依魯提尼(ibrutinib)及阿貝西諾特(Abexinostat)之組合投予該個體。亦提出治療抗依魯提尼型CLL或抗依魯提尼型AML的方法,其係將包含依魯提尼及阿貝西諾特之組合投予該個體。另外提出減少患有CLL或AML之個體發展出依魯提尼抗藥性的方法,或防止患有CLL或AML之個體發展出依魯提尼抗藥性的方法,其係將包含依魯提尼及阿貝西諾特之組合投予該個體。
